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Alcohol doseBackground: The aim of this study was to evaluate short- and long-term outcomes related to dose of alcohol ad-
ministered during alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy
(HOCM). Current guidelines recommend using 1–3mL of alcohol administered in the target septal perforator ar-
tery, but this recommendation is basedmore on practical experience of interventionalists rather than on system-
atic evidence.
Methods: We included 1448 patients and used propensity score to match patients who received a low-dose
(1.0–1.9 mL) versus a high-dose (2.0–3.8 mL) of alcohol during ASA.
Results: The matched cohort analysis comprised 770 patients (n= 385 in both groups). There was a similar oc-
currence of 30-day post-procedural adverse events (13% vs. 12%; p=0.59), and similar all-cause mortality rates
(0.8% vs. 0.5%; p = 1) in the low-dose group and the high-dose group, respectively. In the long-term follow-up
(5.4 ± 4.5 years), a total of 110 (14%) patients died representing 2.58 deaths and 2.64 deaths per 100 patient-
years in the low dose and the high dose group (logrank, p=0.92), respectively. There were no significant differ-
ences in the long-term dyspnea and left ventricular outflow gradient between the two groups. Patients treated
with a low-dose of alcohol underwent more subsequent septal reduction procedures (logrank, p = 0.04).
Conclusions:Matched HOCM patients undergoing ASAwith a low-dose (1.0–1.9 mL) or a high-dose (2.0–3.8 mL)
of alcohol had similar short- and long-term outcomes. A higher rate of repeated septal reduction procedures was
observed in the group treated with a low-dose of alcohol.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Catheter-based therapy of HOCM was introduced 25 years ago and
in the first 3 cases performed by Ulrich Sigwart the dosages of alcohol
were 3 ml in one patient and 5 ml in the other two patients [1]. One
of the most important trends in the continuously developing ASA tech-
nique has been a lowering of the high dose of injected alcohol used in, Czech Republic.
. This is an open access article underearlier studies [2–4]. The current guidelines on hypertrophic cardiomy-
opathy recommend using 1–3mL of alcohol infused into the target sep-
tal perforator artery in controlled fashion [5,6]. However, this
recommendation on alcohol volume is based more on practical experi-
ence of interventionalists, rather than on strong, short- and long-term
systematic evidence.
Therefore, we collected data of patients treated with ASA in nine ex-
perienced European hospital centers, and using propensity score
matching analysis, we evaluated their short- and long-term outcomes
with regard to procedural dose of alcohol used (1–1.9mL vs. 2–3.8mL).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Patients
A total of 1591 patients with symptomatic HOCM underwent first-
time ASA between the years 1997 and 2019 and were enrolled in the
Euro-ASA registry. A total of 143 (9%) patients, who previously
underwent myectomy, or were treated by alcohol dose <1.0 mL
or >3.8 mL, were excluded, giving a total of 1448 patients included
and analyzed in this study. The study was performed in compliance
with the Helsinki II declaration.
2.2. Diagnosis
The diagnosis of HOCMwas established by experienced cardiologists
based on typical clinical, electrocardiographic, echocardiographic, and/
or cardiacmagnetic resonance imaging characteristics [5,6]. All patients
had a baseline LV outflow gradient ≥30 mmHg at rest, and/or
≥50 mmHg induced after provocation.
2.3. Interventions
The therapeutic decision regarding ASA was made after detailed
multidisciplinary evaluation and discussions with the patients. All ASA
procedures were performed by experienced interventional cardiolo-
gists, and details of the myocardial contrast echocardiography-guided
ASA technique have been published in the past [7–9]; desiccated alcohol
96%was used. Therewere no fundamental differences in ASA technique
between centers included in this study. Volume of alcohol injected was
at the discretion of each interventionalist.Table 1
Clinical and echocardiographic characteristics for study population at baseline and at the last c
Unmatched cohorts
Alcohol 1.0–1.9 mL Alcohol 2.0–3.8
N = 465 N = 983
Age, years 60.6 ± 12.3 56.4 ± 14.3
Females, n (%) 262 (56) 442 (45)
Total alcohol volume, ml (range) 1.4 ± 0.3 (1.0–1.9) 2.5 ± 0.5 (2.0–3
Bundle branch block before ASA, n(%) 46 (10) 115 (12)
Pacemaker before ASA, n (%) 22 (5) 31 (3)
ICD before ASA, n (%) 22 (5) 45 (5)
NYHA class
Baseline 2.9 ± 0.5 2.8 ± 0.5
Last clinical check-up 1.8 ± 0.7 1.6 ± 0.7
NYHA class III/IV
Baseline, n (%) 389 (84) 767 (78)
Last clinical check-up, n (%) 65 (14) 117 (12)
Angina, CCS class
Baseline 1.2 ± 1.2 1.1 ± 1.2
Last clinical check-up 0.6 ± 0.8 0.6 ± 0.8
LV outflow gradient at rest, mmHg
Baseline 71.4 ± 39.6 68.7 ± 38.5
Last clinical check-up 16.5 ± 19.8 16.4 ± 21.9
>30 mmHg, n (%) 66 (14) 160 (16)
LV outflow gradient reduction (%) 73 ± 32 73 ± 29
LV end diastolic diameter, mm
Baseline 43.0 ± 6.0 43.3 ± 6.5
Last clinical check-up 45.5 ± 6.2 45.5 ± 6.1
LV ejection fraction, %
Baseline 71 ± 9 70 ± 9
Last clinical check-up 67 ± 9 66 ± 10
Basal septum thickness, mm
Baseline 19.8 ± 3.9 21.1 ± 4.4
Last clinical check-up 15.2 ± 4.2 15.7 ± 4.8
Left atrium diameter, mm
Baseline 46.9 ± 6.3 47.0 ± 7.1
Last clinical check-up 46.2 ± 7.4 46.0 ± 7.3
Median follow-up duration, years (IQR) 3.8 (1.5; 7.3) 4.6 (1.6; 8.3)
1282.4. Study design
Patients were divided into two groups, according to alcohol dose
injected (Table 1). By using propensity score (see below), patients
with injected low alcohol dose of 1.0–1.9mLwerematched to compara-
ble patients with a high alcohol dose of 2.0–3.8 mL in a ratio 1:1.2.5. Follow-up
Demographic, electrocardiographic, echocardiographic and clinical
data were recorded at baseline and during follow-up. Most patients
underwent a post-procedure clinical examination three to six months
after ASA and every year thereafter. The follow-upprogram included re-
cording of symptomsand adverse events, physical examination, electro-
cardiographic, and echocardiographic examination. All clinical adverse
events were confirmed by review of themedical records. The indication
for repeated septal reduction therapy was at the discretion of each par-
ticipating center. Assessing patient survival was done with use of the
National Databases of Deaths and/or was updated by clinical communi-
cation with patients.2.6. Outcomes
Both, short- and long-term outcomes of the matched patients in
both groups were compared. We assessed (i) 30-day major cardiovas-
cular adverse events including electrical defibrillation for VT/VF, or an
appropriate ICD discharge, cardiac tamponade, and permanent pace-
maker implantation; (ii) 30-day all-cause mortality rate; (iii) long-
term all-cause mortality rate; (iv) long-term LV outflow gradient andheck-up.
Matched cohorts
mL P value Alcohol 1.0–1.9 mL Alcohol 2.0–3.8 mL P value
N = 385 N = 385
<0.001 59.8 ± 12.0 59.7 ± 12.8 0.918
<0.001 210 (55) 208 (54) 0.942
.8) <0.001 1.4 ± 0.3 (1.0–1.9) 2.4 ± 0.5 (2.0–3.8) <0.001
0.282 39 (10) 47 (12) 0.423
0.137 13 (3) 17 (4) 0.577
0.89 18 (5) 13 (3) 0.464
0.004 2.9 ± 0.5 2.9 ± 0.5 0.992
0.008 1.8 ± 0.7 1.7 ± 0.7 0.075
0.014 325 (84) 317 (82) 0.498
0.271 55 (14) 47 (12) 0.457
0.036 1.3 ± 1.2 1.2 ± 1.3 0.132
0.215 0.6 ± 0.8 0.7 ± 0.8 0.207
0.256 70.4 ± 39.3 70.5 ± 38.9 0.938
0.618 16.6 ± 20.2 17.1 ± 23.0 0.943
0.352 57 (15) 65 (17) 0.490
0.331 73 ± 31 74 ± 26 0.871
0.365 43.1 ± 6.0 42.9 ± 6.4 0.925
0.875 45.7 ± 6.1 45.1 ± 5.8 0.248
<0.001 71 ± 9 72 ± 9 0.939
0.015 67 ± 9 66 ± 10 0.426
<0.001 19.9 ± 3.8 20.0 ± 3.7 0.533
0.098 15.1 ± 4.1 14.9 ± 4.5 0.279
0.776 47.1 ± 6.3 46.7 ± 7.0 0.373
0.819 46.5 ± 7.4 46.2 ± 7.5 0.610
4.0 (1.6; 7.4) 4.6 (1.7; 8.8)
Fig. 1. Histogram of alcohol doses in the whole ASA cohort.
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(re-ASA or myectomy).2.7. Statistical analysis
All data were assessed and edited by experienced research statisti-
cians. Data are presented as means±standard deviations (±SDs), me-
dians and interquartile range (IQR), and numbers and proportions for
categorical variables. Mann-Whitney test was used to assess the differ-
ence between continuous variables, and the Chi square test between
categorical variables. We calculated a propensity score for the following
baseline variables: sex, age, LV outflow gradient, LV end-diastolic diam-
eter, basal interventricular septum thickness, LV ejection fraction, NYHA
class, implanted ICD or pacemaker. The propensity score was estimated
using a logit model. Matching was performed using 1:1 nearest neigh-
bor method without replacement, which yielded 385 patients with
the low alcohol dose of 1.0–1.9 mL, who were matched with 385 pa-
tients with the high alcohol dose of 2.0–3.8 mL. Cox's proportional haz-
ards model with clustered standard errors was used for the analysis of
time to event. Tofind risk predictors of all-causemortality, the following
baseline variables were evaluated in a univariate model: sex, age, LV
outflow gradient, LV end-diastolic diameter, interventricular septum
thickness, LV ejection fraction, NYHA class 1 or 2, and NYHA class 3 or
4. Subsequently, a multivariable analysis was performed using a back-
ward stepwise algorithm for Cox's proportional hazards model. Esti-
mates for long-term outcomes were made by the Kaplan–Meier
method (including 95% confidence intervals) and differences were
assessed by the log rank test. P value <0.05 was considered statistically
significant. All reported p values were 2-sided. The software PrismTable 2
Causes of deaths during the month after ASA.
Cause Unmatched cohorts
Alcohol 1.0–1.9 mL Alcohol
N = 465 N = 98
Cardiac tamponade, n (%) 1 (0.2) 2 (0.2)
Carcinoma, n (%) 1 (0.2) 0
Sudden cardiac death (ventricular fibrillation), n (%) 1 (0.2) 1 (0.1)
Pulmonary embolism, n (%) 1 (0.2) 1 (0.1)
Stroke, n (%) 0 1 (0.1)
Heart failure, n (%) 0 1 (0.1)
Total, n (%) 4 (0.9) 6 (0.6)
129(release 6.05, GraphPad Software Inc.) and SPSS 25.0.0.1 (IBM Corpora-
tion 2019) were used for statistical analysis.
3. Results
We included and analyzed a total of 1448 patients with obstructive
HCM treated with ASA. In this entire cohort, the mean dose of alcohol
administered during ASA was 2.1 ± 0.7 mL (Fig. 1). The correlation be-
tween alcohol dose and septal thickness in the whole population was
very weak (r = 0.13; p < 0.01).
We identified 465 (32%) patients treated with the low dose of alco-
hol (1.0–1.9mL) and compared these to 983 (68%) patients treatedwith
the high dose of alcohol (2.0–3.8 mL) (unmatched cohorts; Table 1).
The propensity-matched cohort analysis comprised 770 (53%) pa-
tients divided into two groups including the low-dose group (alcohol
dose 1.0–1.9 mL, n = 385 patients) and the high-dose group (alcohol
dose 2.0–3.8 mL, n = 385 patients) (Table 1). In the matched groups,
there were significant differences neither in the baseline rate of im-
planted pacemakers or ICDs (8% in the low-dose group vs. 8% in the
high-dose group; p = 1) nor in the preexisting bundle branch blocks
(10% in the low-dose group vs. 12% in the high-dose group; p = 0.42).
3.1. Short-term results
In the matched cohorts, the 30-day mortality rate was 0.6% (0.8% in
the low-dose group vs. 0.5% in the high-dose group; p = 1). Causes of
death are summarized in Table 2. There were no significant differences
in the early occurrences of VT/VF requiring electrical cardioversion or
appropriate ICD discharge, cardiac tamponade, or permanent pace-
maker implantation, respectively, between the two groups (Table 3).
3.2. Long-term results
No patients were lost to follow-up. In the matched cohorts, the me-
dian follow-up durationwas 4.5 years (IQR 1.8–8.3 years), and a total of
110 (14%) patients died in the course of 4143 patient-years,
representing 2.58 deaths and 2.64 deaths per 100 patient-years in the
low-dose and the high-dose group, respectively. The Kaplan-Meier
curves of all-causemortality rates are shown in Fig. 2with no significant
difference between the matched groups (logrank, p = 0.92).
In multivariable analysis, the predictors of all-cause mortality were
female sex, age>60 years, baseline septum thickness ≥22mmand base-
line LV outflow gradient ≥90 mmHg (Table 4).
In the matched groups, there were no significant differences in the
long-term NYHA class and LV outflow gradient (Table 1).
A total of 80 (10%) patients in the matched groups underwent re-
peated septal reduction therapy because of insufficient symptom relief
and residual LV outflow gradient after the initial ASA (48 patients in
the low-dose group vs. 32 patients in the high-dose group). The
Kaplan-Meier curves presenting septal reduction re-intervention rates
are shown in Fig. 3 and the low-dose group experienced significantly
more reinterventions (logrank, p = 0.04).Matched cohorts
2.0–3.8 mL P value Alcohol 1–0-1.9 mL Alcohol 2.0–3.8 mL P value
3 N = 385 N = 385
1.000 1 (0.3) 1 (0.3) 1.000
0.321 1 (0.3) 0 1.000
0.539 0 0 1.000
0.539 1 (0.3) 0 1.000
1.000 0 0 1.000
1.000 0 1 (0.3) 1.000
0.735 3 (0.8) 2 (0.5) 1.000
Table 3
Non-hierarchical occurrence of major cardiovascular adverse events during the first month after ASA.
Event Unmatched cohorts Matched cohorts
Alcohol 1.0–1.9 mL Alcohol 2.0–3.8 mL P value Alcohol 1–0-1.9 mL Alcohol 2.0–3.8 mL P value
N = 465 N = 983 N = 385 N = 385
Defibrillation for VT/VF or appropriate ICD discharge, n (%) 9 (1.9) 11 (1.1) 0.232 7 (1.8) 6 (1.6) 1.000
Cardiac tamponade, n (%) 8 (1.7) 8 (0.8) 0.175 7 (1.8) 4 (1.0) 0.546
New permanent pacemaker, n (%) 50 (10.8) 102 (10.4) 0.854 37 (9.6) 35 (9.1) 0.902
Total, n (%) 67 (14.4) 121 (12.3) 0.277 51 (13.2) 45 (11.7) 0.586
Fig. 2. Central illustration. The Kaplan-Meier curves with 95% confidence intervals for the
long-term survival of ASA patients treated with the low-dose (1.0–1.9 mL) or the high-
dose (2.0–3.8 mL) of alcohol (p= 0.92).
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To the best of our knowledge, this is the largest reported study to com-
pare short- and long-term outcomes of ASA patients treated with low- or
high-doses of alcohol. The most important findings of this study were as
follows: [1] Propensity-matched patients treated with the low-
(1.0–1.9 mL) or the high-dose (2.0–3.8 mL) of alcohol had similar 30-
day post-procedural occurrence of major adverse events, including VT/
VF requiring electrical defibrillation or appropriate ICD discharge, rate of
permanent pacemaker implantation, or occurrence of cardiac tamponade,
[2] 30-day all-cause mortality rates were also similar between the two
groups. [3] In the long-term follow-up, the matched patients had similar
all-cause mortality rates, NYHA classes, and LV outflow pressure gradi-
ents, and [4] patients treated with the low dose of alcohol had a higher
rate of repeated septal reduction therapy.
Existing evidence of alcohol dose-related outcomes of ASA has been
derived from a small single-center randomized study [10,11] and single-
center institutional registries [13–16]. Early after the introduction of
ASA in the mid-1990s, higher doses (mean dose ≥2.8 mL) of desiccatedTable 4
Predictors of all-cause mortality (n = 770).
HR (95% C
Females; n = 418 1.6 (1.0; 2
Age
60–69 years; n = 194 1.9 (1.1; 3
≥70 years; n = 179 3.3 (2.1; 5
LV septum thickness ≥22, mm; n = 212 1.6 (1.1; 2
LV outflow gradient ≥90 mmHg; n = 224 1.7 (1.1; 2
130alcohol were used [12–14]. Later, Kuhn et al. reported the 10-year experi-
encewith ASA (n=264) in Germany and comparedmid-term outcomes
of ASA patients treated in the “low-dose” and “high-dose” eras. These in-
vestigators concluded that patients who were given a higher amount of
alcohol (>2 mL) had a higher mortality rate than those given lower
doses [15]. Subsequently, a small, single-center, prospective, randomized
study did not find any differences in hemodynamic effects and long-term
survival between patients with low- and high doses of alcohol [10,11].
Similarly, Liebregts et al. retrospectively evaluated patients treated in a
non-randomized fashionwith low- (≤2mL) or high-dose (>2mL) of alco-
hol (n=267) and found that the long-term survival and rates of adverse
arrhythmic events were similar [16]. Even though all these studies and
clinical experience from institutional registries led to the widely held
view to use lower doses of alcohol to decrease post-ASA complications
[17–20], there is still an ongoing debate regarding the appropriate alcohol
dose for ASA.
Optimally, the alcohol dose injected during ASA should ensure devel-
opment of adequate necrosis in the thickened subaortic myocardium,
leading to myocardial shrinkage and significant widening of the LV out-
flow tract. Additionally, the extent of post-ASA myocardial scar tissue
should not induce significant arrhythmogenic events or heart failure. It
is important to note, however, that apart from the amount of injected al-
cohol, a range of factors including, for example, anatomy of the septal
branches, mechanism of subaortic dynamic obstruction and interplay
with the mitral apparatus, papillary muscles abnormalities, magnitude
of septal thickness, and septal hypertrophy geometry play important
roles in decision-making to tailor optimal therapy for each individual
HOCM patient [21–25]. Since these and other unmeasured factors were
not taken into account in our study it is impossible to establish a specific
alcohol dose suitable for all HOCM patients treated with ASA. However,
this study demonstrates that the predominant alcohol doses used for
ASAduring the last twodecades are safe and effective, and the results sug-
gest that for this range of alcohol doses, the specific dose volume plays
minor role in the long-term outcomes of ASA patients.
In current clinical practice the principal focus remains on optimal se-
lection of patients suitable for ASA. If ASA is selected as treatment strat-
egy, precise intra-procedural determination of the target septal branch
perfusion territory to ensure correct localization of alcohol is more im-
portant for long-term procedural success than the precise alcohol dose
in the 1.0–3.8 mL range.
In the previous analysis which included 1275 patients treated with






Fig. 3. The Kaplan-Meier curves with 95% confidence intervals for the long-term freedom
of repeated septal reduction therapy of ASA patients treated with the low-dose
(1.0–1.9 mL) or the high-dose (2.0–3.8 mL) of alcohol (p = 0.04).
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complete heart block, and (ii) reduction of LV obstruction [8]. However,
in the present study we have excluded patients who were treated with
either ultra-low (<1mL) or ultra-high (>3.8 mL) alcohol doses that are
currently not used anymore. Consequently, the only significant differ-
ence between the propensity-matched ASA groups was an increased
need for repeated septal reduction therapies in the patients treated
with the low-dose of alcohol. This finding is in line with results of previ-
ous studies that demonstrated a positive correlation between alcohol
dose and subsequent myocardial biomarker release indicative of the
amount of myocardial necrosis [11,26,27]. Thus, from the clinical point
of view, an effort to minimize the final post-ASA myocardial scar by
using lower doses of alcohol might lead to insufficient tissue ablation
and increased need of repeated ASA ormyectomy [3,11,28]. Conversely,
a more aggressive approach might reduce repeated procedures.
This study has several limitations. First, propensity score-matching
has inherent limitations and does not make up for a prospective, ran-
domized, controlled trial. However, results of this study are consistent
with the only published randomized study [10,11], which, however,
comprised ten times less patients from a single center. Moreover,
large randomized trials of alcohol doses for ASA are unlikely to be per-
formed in the near future. Second, some diversity exists in the field
with respect to interpretation and implementation of the existing evi-
dence on ASA, e.g. patient selection, myectomy as an alternative inva-
sive strategy, and some differences in ASA technique, that might limit
the generalizibility of our results [9,29]. On the other hand, these differ-
ences ensured the diversity of interventional techniques used in this
international study.
5. Conclusions
Propensity-matched obstructive HCM patients treated with low-
dose (1.0–1.9 mL) or high-dose (2.0–3.8 mL) of alcohol during ASA
had similar short- and long-term outcomes, except for a higher rate of
repeated septal reduction procedures in the group treated with the
low-dose of alcohol.
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